

**Human Interferon-beta 1b protein (Recombinant) (STJP000324)**  
STJP000324

**GENERAL INFORMATION**


<b>Product Type</b>	Proteins
<b>Short Description</b>	Recombinant-Human Interferon-beta 1b-protein was developed from cho cells. For use in research applications.
<b>Host/Source</b>	CHO cells

**PRODUCT PROPERTIES**


<b>Concentration</b>	
<b>Formulation</b>	Lyophilised from 0.2 Mu m filtered solution containing mM NaOAc pH.5.
<b>Purification</b>	
<b>Dilution Range</b>	>95%, as determined by SDS-PAGE and HPLC NA
<b>Storage</b>	Can be stored in working aliquots at°C-°C C for one month, or at-20°C C for six months, with a carrier protein without detectable
<b>Instruction</b>	loss of activity. Avoid repeated freeze/thaw cycles. NA

**TARGET INFORMATION**


<b>Gene ID</b>	3456
<b>Gene Symbol</b>	IFNB1
<b>Uniprot ID</b>	IFNB_HUMAN
<b>Immunogen</b>	
<b>Sequence</b>	




Following the initial culture period, islets were cultured for an additional 6824 hours in CMRL 1066 containing antibiotics, 2 mM glutamine and one of the following supplements: 0.5 mM sodium palmitate solubilized in 0.5% (weight/volume) fatty acid and lipopolysaccharide free bovine serum albumin (BSA); recombinant human Interleukin 1beta (IL-1A (50 units/ml) and Interferon-gamma (IFN-Gamma) (1,000 units/ml); 100 mM hydrogen peroxide; 2 mM DETA/NO or 10 mM streptozotocin (STZ). To some of the groups 10 AμM of Imatinib was added at different time points prior to the addition of test substances given above. To controls equal amounts of vehicle (DMSO) were supplemented.



Interferon gamma (IFN-Gamma) 50 Mu l (100 ng/ml) was added to each dish in the experimental studies. The cytoplasmic and nuclear extracts were washed with ice-cold PBS and lysed in a 0.5 ml/well lysis buffer (150 mmol/l NaCl, 20 mmol/l Tris, pH 7.5, 0.1% Triton X-100, 1 mmol/l phenylmethylsulfonyl fluoride [PMSF] and 10 Mu g/ml aprotinin) as modified from the reports of Kim et al. and Moon et al. [



E) Recombinant Type III Interferons in the absence of CM at the same concentrations as found in the CM (IL-28A/IFN Lambda 2: 1500 pg/mL; IL-28B/IFN Lambda 3: 10 pg/mL; IL-29/IFN Lambda 1: 500 pg/mL) were added to JFH-1 infected Huh7.5.1 cells.



Venous blood was collected prior to chemotherapy or at least one month following chemotherapy. For the offspring (HLA haploidentical donors), the routine blood tests, and liver and kidney function tests were normal and negative for hepatitis A virus-IgM, hepatitis B surface antigen antibody, hepatitis B e-antibody, hepatitis B core-hepatitis C virus (HCV) -HCV-IgG, Syphilis-and human immunodeficiency virus-. As reported in our previous study (2 atmosphere). On the day of culture, 1,000 U/ml human recombinant interferon-Gamma, 500 U/ml recombinant human interleukin (rhIL)-1 Alpha and 1,000 U/ml rhIL-2 (Guangdong Pharmaceutical Co. . . ) were added. Four days later, 1,000 U/ml mL-2 was added and the cells were transferred into a G1-1610 culture bag. Cell growth was observed every other day and cells were stained with 0.4% trypan blue and the viable cells were counted. Following 18 days of culture, cells were infused once daily (>1A109 cells; viability rate, >95%). A cycle of treatment is

This product is suitable for in-vitro studies under the RESEARCH USE ONLY [RUO] licence. This product must not be used as for diagnostic or other medical purposes.  
St John's Laboratory Ltd, Knowledge Dock Business Centre, University Way, London, E16 2RD | Tel: 0208 223 3081